» Articles » PMID: 22331471

Characterization of Critical Domains Within the Tumor Suppressor CASZ1 Required for Transcriptional Regulation and Growth Suppression

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2012 Feb 15
PMID 22331471
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

CASZ1 is a zinc finger (ZF) transcription factor that is critical for controlling the normal differentiation of subtypes of neural and cardiac muscle cells. In neuroblastoma tumors, loss of CASZ1 is associated with poor prognosis and restoration of CASZ1 function suppresses neuroblastoma tumorigenicity. However, the key domains by which CASZ1 transcription controls developmental processes and neuroblastoma tumorigenicity have yet to be elucidated. In this study, we show that loss of any one of ZF1 to ZF4 resulted in a 58 to 79% loss in transcriptional activity, as measured by induction of tyrosine hydroxylase promoter-luciferase activity, compared to that of wild-type (WT) CASZ1b. Mutation of ZF5 or deletion of the C-terminal sequence of amino acids (aa) 728 to 1166 (a truncation of 38% of the protein) does not significantly alter transcriptional function. A series of N-terminal truncations reveals a critical transcriptional activation domain at aa 31 to 185 and a nuclear localization signal at aa 23 to 29. Soft agar colony formation assays and xenograft studies show that WT CASZ1b is more active in suppressing neuroblastoma growth than CASZ1b with a ZF4 mutation or a deletion of aa 31 to 185. This study identifies key domains needed for CASZ1b to regulate gene transcription. Furthermore, we establish a link between loss of CASZ1b transcriptional activity and attenuation of CASZ1b-mediated inhibition of neuroblastoma growth and tumorigenicity.

Citing Articles

Epigenetic modification of Castor zinc finger 1 (CASZ1) is associated with tumor microenvironments and prognosis of clear cell renal cell carcinoma.

Li F, Liang J, Wei X Int J Surg. 2024; 111(1):988-997.

PMID: 39235847 PMC: 11745609. DOI: 10.1097/JS9.0000000000002070.


Role of the CASZ1 transcription factor in tissue development and disease.

Liu T, Li T, Ke S Eur J Med Res. 2023; 28(1):562.

PMID: 38053207 PMC: 10696751. DOI: 10.1186/s40001-023-01548-y.


: Current Implications in Cardiovascular Diseases and Cancers.

Jian H, Poetsch A Biomedicines. 2023; 11(7).

PMID: 37509718 PMC: 10377389. DOI: 10.3390/biomedicines11072079.


CASZ1 promotes migration, invasion, and metastasis of lung cancer cells by controlling expression of ITGAV.

Taheri Baghmisheh S, Wu Y, Wu J, Hsu K, Chen Y, Hong T Am J Cancer Res. 2023; 13(1):176-189.

PMID: 36777515 PMC: 9906072.


Identification of a Novel de Novo Variant in the CASZ1 Causing a Rare Type of Dilated Cardiomyopathy.

Orlova A, Guseva D, Ryzhkova O Int J Mol Sci. 2022; 23(20).

PMID: 36293425 PMC: 9603937. DOI: 10.3390/ijms232012506.


References
1.
Brody T, Odenwald W . Cellular diversity in the developing nervous system: a temporal view from Drosophila. Development. 2002; 129(16):3763-70. DOI: 10.1242/dev.129.16.3763. View

2.
Christine K, Conlon F . Vertebrate CASTOR is required for differentiation of cardiac precursor cells at the ventral midline. Dev Cell. 2008; 14(4):616-23. PMC: 2807748. DOI: 10.1016/j.devcel.2008.01.009. View

3.
Grotzer M, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A . Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets. 2009; 9(2):176-88. DOI: 10.2174/156800909787580962. View

4.
De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M . Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med. 1998; 188(9):1763-8. PMC: 2212516. DOI: 10.1084/jem.188.9.1763. View

5.
Brennan P, Donev R, Hewamana S . Targeting transcription factors for therapeutic benefit. Mol Biosyst. 2008; 4(9):909-19. DOI: 10.1039/b801920g. View